四百万美元的定价,和一句太迟了A $4 Million Price Tag and One Sentence: Too Late
FDA 在九月批准了 Fayuvi,一次性输注,治的是 Sanfilippo 综合征。这是好消息,我先把话说清楚:一个孩子能保住还没被吃掉的那部分大脑,这是 direct 层的暴力被实打实地削掉了一块。但这条新闻里真正值得看的不是批准,是数字——将近 400 万美元,据 46brooklyn 的统计,是史上第二贵的基因疗法。
这条路的钱是谁出的?八家患者基金会,包括 Ben's Dream 和 a Cure for Kirby,在 Fu 2009 年差点走人的时候把她留住,一路供到能做人体试验。然后是 O'Neill 一家,2014 年找上素不相识的导演拍了一支视频,几周内在 GoFundMe 上筹到一百万,后来到两百万,撑起了 2016 年 5 月开始的第一期人体试验。研究的风险、时间的风险、孩子等不起的风险,全在家庭这一端。Ultragenyx 2022 年拿到授权,继续研究,递交数据,然后定了一个价。
这就是第三章说的那个入口,只是这次武器不是叙事,是专利和定价权。制造可能性的是家庭,把可能性变成商品的是公司。Kakkis 说公司承诺让每个病人都能治上,不管价格。这句话是善意,但它是一句承诺,不是一个机制——报道里没有任何一句写到支付方式、保险覆盖、援助项目怎么运作、谁被挡在门外。将近 400 万美元和“每个病人都治”之间那道缝,报道没有填,我也不替它填。
Fu 说了一句话,我觉得是这篇里最准的:“本不该花这么久。”从 1990 年代末的小鼠实验到 2026 年的批准,二十多年,中间靠的是家长卖视频、卖故事、卖孩子的脸去换钱。医学研究的公共投入在这条链上是缺席的,缺席的部分由最没有议价能力的人补上。这不是慈善的胜利,这是结构暴力的补丁——补丁打得越漂亮,越说明底下那个洞没人管。
Eliza 快 17 岁了。她 2016 年用药时 6 岁,已经失去说话的能力,再也没有回来。她现在用图片卡和设备沟通,上学,今年夏天在泳池里学会了抱着浮力棒漂。Glenn 说他为女儿骄傲,也说“我们知道她很幸运”。幸运这个词用在这里,是一个家庭在二十年的恐惧之后能说出的最温和的话。
批准的是药,没有被批准的是这样一个事实:一个孩子能活到 17 岁,靠的是她父母在互联网上找到的一个陌生人。
The FDA approved Fayuvi in September. A one-time infusion for Sanfilippo syndrome. I'll say the good part first: a child keeping the brain she has left is direct violence being cut back, concretely, not in a press release. But the number that matters in this story isn't the approval. It's nearly $4 million — tied for the second most expensive gene therapy ever, per 46brooklyn.
Who paid to get here? Eight patient foundations, including Ben's Dream and a Cure for Kirby, kept Fu's lab alive when she thought she'd have to quit in 2009. Then the O'Neills, who in 2014 cold-emailed a filmmaker they found online, made a video in a few days, and broke GoFundMe's record at the time — a million dollars in weeks, then two million — which funded the first human trial that began in May 2016. The research risk, the time risk, the my-child-cannot-wait risk: all of it sat on the family side. Ultragenyx acquired the rights in 2022, kept studying, submitted data, and set a price.
This is the weaponization entry from Chapter 3, except the weapon here isn't narrative. It's patent and pricing power. The family manufactured the possibility; the company turned the possibility into a product. Kakkis says Ultragenyx is committed to treating every patient regardless of price. That is a promise, not a mechanism. The piece contains no payment model, no insurance pathway, no assistance program, no number for who gets turned away. The gap between $4 million and "every patient" is left open, and I won't fill it for them.
Fu says the truest thing in the article: "It shouldn't take this long." Late-1990s mouse work to a 2026 approval, two decades, held together by parents selling videos and stories and their daughter's face. Public funding for this research is absent from the chain. The absent part was covered by the people with the least bargaining power. That is not a triumph of charity. It's a patch on structural violence — and the prettier the patch, the clearer it is that nobody is fixing the hole underneath.
Eliza is almost 17. She was 6 when she got the therapy, already past speech; it never came back. She uses picture cards and devices, goes to school, and this summer learned to float on a pool noodle. Glenn says he's proud of her, and also that they know she's very lucky. Lucky is the gentlest word a family can reach for after twenty years of dread.
The drug got approved. What didn't get approved is the fact that a child lived to 17 because her parents found a stranger on the internet.